{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(3)"],"submitter":["Ghasemi DR"],"pubmed_abstract":["Medulloblastoma is an embryonal pediatric brain tumor and can be divided into at least four molecularly defined groups. The category non-WNT/non-SHH medulloblastoma summarizes medulloblastoma groups 3 and 4 and is characterized by considerable genetic and clinical heterogeneity. New therapeutic strategies are needed to increase survival rates and to reduce treatment-related toxicity. We performed a noncomprehensive targeted review of the current clinical trial landscape and literature to summarize innovative treatment options for non-WNT/non-SHH medulloblastoma. A multitude of new drugs is currently evaluated in trials for which non-WNT/non-SHH patients are eligible, for instance immunotherapy, kinase inhibitors, and drugs targeting the epigenome. However, the majority of these trials is n"],"journal":["Cancers"],"pagination":["679"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8833659"],"repository":["biostudies-literature"],"pubmed_title":["The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma."],"pmcid":["PMC8833659"],"pubmed_authors":["Fleischhack G","Pajtler KW","Ghasemi DR","Milde T"],"additional_accession":[]},"is_claimable":false,"name":"The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma.","description":"Medulloblastoma is an embryonal pediatric brain tumor and can be divided into at least four molecularly defined groups. The category non-WNT/non-SHH medulloblastoma summarizes medulloblastoma groups 3 and 4 and is characterized by considerable genetic and clinical heterogeneity. New therapeutic strategies are needed to increase survival rates and to reduce treatment-related toxicity. We performed a noncomprehensive targeted review of the current clinical trial landscape and literature to summarize innovative treatment options for non-WNT/non-SHH medulloblastoma. A multitude of new drugs is currently evaluated in trials for which non-WNT/non-SHH patients are eligible, for instance immunotherapy, kinase inhibitors, and drugs targeting the epigenome. However, the majority of these trials is n","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-04T07:55:05.949Z","creation":"2025-02-19T05:04:43.922Z"},"accession":"S-EPMC8833659","cross_references":{"pubmed":["35158947"],"doi":["10.3390/cancers14030679"]}}